ReviewBritish journal of clinical pharmacology2014
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Geographical variability in dabigatran dosing within New Zealand.Internal medicine journal · 2026Article
- Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.ACS omega · 2026Article
- Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?British journal of clinical pharmacology · 2021Review
- Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).Biomedicines · 2021Review
- Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation.TH open : companion journal to thrombosis and haemostasis · 2019Article
- Treating patients on new anticoagulant drugs.Australian prescriber · 2017Article
- The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Scientific reports · 2016Article
- Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.Thrombosis journal · 2016Article
- Analgesic use before and after oral anticoagulant initiation--a population-based study in Finland.European journal of clinical pharmacology · 2015Article
- Enhanced elimination of dabigatran through extracorporeal methods.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2015Review
- Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Drugs in R&D · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dabigatran is an oral anticoagulant that is increasingly used for atrial fibrillation (AF). Presently, many authorities state that routine laboratory coagulation monitoring is not required. However, data have recently been published demonstrating that higher trough plasma dabigatran concentrations are associated with lower thromboembolic and higher haemorrhagic event rates. Using these data, we simulate a range of AF patients with varying risks for these events and derive a target range of trough plasma dabigatran concentrations (30-130 μg l(-1) ). Finally, we propose that a conventional screening coagulation assay, the thrombin time (TT), can be used to discern whether or not patients are within this range of dabigatran concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.